ADMA Biologics ADMA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| ADMA Bio Manufacturing | $493.17M0.0% | $493.14M+2.4% | $481.79M+3.5% | $465.32M+3.5% | $449.55M+8.1% | |
| Plasma Collection Centers | $16.7M-2.0% | $17.03M+151% | $6.77M-23.5% | $8.86M-9.9% | $9.83M-6.4% | |
| Nonoperating Income Expense by Business | ||||||
| ADMA Bio Manufacturing | -$323K-61.5% | -$200K+25.4% | -$268K+11.6% | -$303K-45.7% | -$208K-19.5% | |
| Plasma Collection Centers | $58K+680% | -$10K-900% | -$1K0.0% | -$1K+75.0% | -$4K+20.0% | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest by Business | ||||||
| ADMA Bio Manufacturing | 25,217,200,000%+1,709,300,000pp | 23,507,900,000%+4,292,400,000pp | 19,215,500,000%+228,100,000pp | 18,987,400,000%-149,100,000pp | 19,136,500,000%+1,653,900,000pp | |
| Plasma Collection Centers | 243,000,000%+779,300,000pp | -536,300,000%-7,900,000pp | -528,400,000%-50,300,000pp | -478,100,000%+8,800,000pp | -486,900,000%+17,200,000pp | |
| Cost Of Revenue by Business | ||||||
| ADMA Bio Manufacturing | $179.75M-10.1% | $199.86M-6.7% | $214.21M+0.1% | $213.96M+3.0% | $207.67M+6.2% | |
| Plasma Collection Centers | $17.69M+0.8% | $17.55M+148% | $7.07M-20.6% | $8.9M-12.5% | $10.17M-10.0% | |
| Total Assets by Business | ||||||
| ADMA Bio Manufacturing | $1.64B+6.4% | $1.54B+10.9% | $1.39B+11.0% | $1.25B+9.6% | $1.14B+4.7% | |
| Plasma Collection Centers | $109.94M-2.1% | $112.33M-1.7% | $114.31M-5.1% | $120.47M-3.6% | $124.92M-4.8% | |
| Selling And Marketing Expense by Business | ||||||
| ADMA Bio Manufacturing | $27.89M+4.3% | $26.74M+5.4% | $25.37M+9.7% | $23.12M+6.3% | $21.76M+8.0% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| ADMA Bio Manufacturing | $20.22M-9.7% | $22.4M-6.7% | $24.02M+130% | $10.43M+8.6% | $9.61M+32.7% | |
| Plasma Collection Centers | $556K+1.1% | $550K+29.7% | $424K+201% | $141K-31.6% | $206K+2.0% | |
| General And Administrative Expense by Business | ||||||
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| ADMA Bio Manufacturing | $6.53M+37.2% | $4.76M+26.1% | $3.78M+42.0% | $2.66M+21.5% | $2.19M+20.7% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Revenue by Geography | ||||||
| Non Us | $3.1M-49.2% | $6.11M-15.0% | $7.18M-40.3% | $12.03M-27.1% | $16.49M+1.2% | |
| US | $506.76M+0.5% | $504.07M+4.7% | $481.38M+4.2% | $462.15M+4.3% | $442.89M+8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ADMA Biologics break its business down?
- ADMA Biologics (ADMA) reports business acquisitions pro forma revenue by business across 2 parts — ADMA Bio Manufacturing and Plasma Collection Centers. Each is extracted from the segment footnotes and tracked over time.
- Where does ADMA Biologics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ADMA Biologics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.